{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:45:43Z","timestamp":1794573943245,"version":"4.9.1"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prostate cancer guidelines often recommend obtaining magnetic resonance imaging (MRI) before a biopsy, yet MRI access is limited. To date, no randomized clinical trial has compared the use of novel biomarkers for risk estimation vs MRI-based diagnostic approaches for prostate cancer screening.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate biomarker-based risk estimation (Stockholm3 risk scores or prostate-specific antigen [PSA] levels) with systematic biopsies vs an MRI-enhanced strategy (PSA levels and MRI with systematic and targeted biopsy) for the detection of clinically significant prostate cancer in a screening setting.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This open-label randomized clinical trial conducted in Stockholm, Sweden, between April 4, 2018, and December 10, 2020, recruited men aged 50 to 74 years with no history of prostate cancer. Participants underwent blood sampling for PSA and Stockholm3 tests to estimate their risk of clinically significant prostate cancer (Gleason score \u22653\u2009+\u20094). After the blood tests were performed, participants were randomly assigned in a 2:3 ratio to receive a Stockholm3 test with systematic biopsy (biomarker group) or a PSA test followed by MRI with systematic and targeted biopsy (MRI-enhanced group). Data were analyzed from September 1 to November 5, 2023.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n In the biomarker group, men with a Stockholm3 risk score of 0.15 or higher underwent systematic biopsies. In the MRI-enhanced group, men with a PSA level of 3 ng\/mL or higher had an MRI and those with a Prostate Imaging\u2013Reporting and Data System (PI-RADS) score of 3 or higher (range: 1-5, with higher scores indicating a higher likelihood of clinically significant prostate cancer) underwent targeted and systematic biopsies.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcome was detection of clinically significant prostate cancer (Gleason score \u22653\u2009+\u20094). Secondary outcomes included detection of clinically insignificant cancer (Gleason score \u22646) and the number of biopsy procedures performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 12\u202f743 male participants (median [IQR] age, 61 [55-67] years), 5134 were assigned to the biomarker group and 7609 to the MRI-enhanced group. In the biomarker group, 8.0% of men (413) had Stockholm3 risk scores of 0.15 or higher and were referred for systematic biopsies. In the MRI-enhanced group, 12.2% of men (929) had a PSA level of 3 ng\/mL or higher and were referred for MRI with biopsies if they had a PI-RADS score of 3 or higher. Detection rates of clinically significant prostate cancer were comparable between the 2 groups: 2.3% in the biomarker group and 2.5% in the MRI-enhanced group (relative proportion, 0.92; 95% CI, 0.73-1.15). More biopsies were performed in the biomarker group than in the MRI-enhanced group (326 of 5134 [6.3%] vs 338 of 7609 [4.4%]; relative proportion, 1.43 [95% CI, 1.23-1.66]), and more indolent prostate cancers were detected (61 [1.2%] vs 41 [0.5%]; relative proportion, 2.21 [95% CI, 1.49-3.27]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Findings of this randomized clinical trial indicate that combining a Stockholm3 test with systematic biopsies is comparable with MRI-based screening with PSA levels and systematic and targeted biopsies for detection of clinically significant prostate cancer, but this approach resulted in more biopsies as well as detection of a greater number of indolent cancers. In regions where access to MRI is lacking, the Stockholm3 test can aid in selecting patients for systematic prostate biopsy.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03377881<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.7131","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:31:59Z","timestamp":1713785519000},"page":"e247131","source":"Crossref","is-referenced-by-count":28,"title":["Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening"],"prefix":"10.1001","volume":"7","author":[{"given":"Lars","family":"Bj\u00f6rnebo","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Discacciati","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Falagario","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari T.","family":"Vigneswaran","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"J\u00e4derling","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Diagnostic Radiology, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Sciences, Danderyd Hospital, Danderyd, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lantz","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"issue":"9959","key":"zoi240272r1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"zoi240272r2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240272r3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head comparison of transrectal ultrasound\u2013guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance\u2013guided biopsy in biopsy-na\u00efve men with elevated prostate\u2013specific antigen: a large prospective multicenter clinical study.","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"10","key":"zoi240272r4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis.","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi240272r5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening.","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240272r7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN Guidelines insights: prostate cancer early detection, version 1.2023.","volume":"21","author":"Moses","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi240272r8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JU.0000000000003492","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part II: considerations for a prostate biopsy.","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"zoi240272r9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/radiol.2017152877","article-title":"What are we missing? false-negative cancers at multiparametric MR imaging of the prostate.","volume":"286","author":"Borofsky","year":"2018","journal-title":"Radiology"},{"issue":"3","key":"zoi240272r10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1148\/radiol.2016152542","article-title":"Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists.","volume":"280","author":"Rosenkrantz","year":"2016","journal-title":"Radiology"},{"issue":"1","key":"zoi240272r11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"issue":"3","key":"zoi240272r12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.eururo.2020.04.016","article-title":"Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence.","volume":"78","author":"Vickers","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"zoi240272r13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eururo.2021.06.026","article-title":"Effects of magnetic resonance imaging targeting on overdiagnosis and overtreatment of prostate cancer.","volume":"80","author":"Vickers","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"zoi240272r14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bju.2017.120.issue-1","article-title":"Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.","volume":"120","author":"Loeb","year":"2017","journal-title":"BJU Int"},{"issue":"7","key":"zoi240272r15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"zoi240272r16","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.","volume":"16","author":"Gr\u00f6nberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi240272r17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy.","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi240272r18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score.","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur Urol"},{"issue":"9","key":"zoi240272r19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi240272r20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027816","article-title":"Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? protocol of the randomised study STHLM3MRI.","volume":"9","author":"Nordstr\u00f6m","year":"2019","journal-title":"BMJ Open"},{"issue":"1","key":"zoi240272r21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi240272r22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.eururo.2017.12.028","article-title":"The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential.","volume":"74","author":"Str\u00f6m","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"zoi240272r23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jacr.2013.05.006","article-title":"Prostate MRI: access to and current practice of prostate MRI in the United States.","volume":"11","author":"Leake","year":"2014","journal-title":"J Am Coll Radiol"},{"issue":"13","key":"zoi240272r24","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/cncr.32821","article-title":"Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance.","volume":"126","author":"Shoag","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"zoi240272r25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2214\/AJR.22.28152","article-title":"Variability of prostate MRI charges among U.S. hospital-based facilities.","volume":"220","author":"Brant","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"zoi240272r26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/02813432.2020.1802139","article-title":"Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system\u2014the Stavanger experience.","volume":"38","author":"Viste","year":"2020","journal-title":"Scand J Prim Health Care"},{"issue":"4","key":"zoi240272r27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.2024.42.4_suppl.262","article-title":"Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: a multicentered, prospective trial.","volume":"42","author":"Vigneswaran","year":"2024","journal-title":"J Clin Oncol"},{"key":"zoi240272r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.09.016","article-title":"Prospective multicenter validation of the Stockholm3 test in a central European cohort.","author":"Elyan","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"1","key":"zoi240272r29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","article-title":"Cost-effectiveness of the Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study.","volume":"82","author":"Hao","year":"2022","journal-title":"Eur Urol"},{"key":"zoi240272r6","unstructured":"Mottet? N, Cornford? P, van den Bergh? RCN, ; European Association of Urology; European Association of Nuclear Medicine; European Society for Radiotherapy and Oncology; European Society of Urogenital Radiology; International Society of Urological Pathology; International Society of Geriatric Oncology. Guidelines on prostate cancer. European Association of Urology. Accessed September 25, 2023. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/diagnostic-evaluation"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2817859\/bjrnebo_2024_oi_240272_1713196766.31739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:32:08Z","timestamp":1713785528000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2817859"}},"subtitle":["The STHLM3-MRI Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7131","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]}}}